ALTO NEUROSCIENCE INC (ANRO) Stock Price, Quote, News and Overview
NYSE:ANRO - New York Stock Exchange, Inc. - US02157Q1094 - Common Stock - Currency: USD
ANRO Quote, Performance and Key Statistics
3.55
-0.4 (-10.13%)
The current stock price of ANRO is 3.55 USD. In the past month the price decreased by -10.13%. In the past year, price decreased by -74.2%.
ANRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.89 | 824.51B | ||
| JNJ | JOHNSON & JOHNSON | 16.69 | 401.33B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.18 | 386.95B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.41 | 240.28B | ||
| MRK | MERCK & CO. INC. | 12.39 | 239.09B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.56 | 228.26B | ||
| PFE | PFIZER INC | 8.59 | 151.49B | ||
| SNY | SANOFI-ADR | 14.24 | 148.55B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 53.59 | 123.97B | ||
| GSK | GSK PLC-SPON ADR | 8.29 | 81.62B | ||
| ZTS | ZOETIS INC | 28.78 | 76.29B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.71 | 47.88B |
Related stock screener links
About ANRO
Company Profile
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 88 full-time employees. The company went IPO on 2024-02-02. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
Company Info
ALTO NEUROSCIENCE INC
650 Castro Street, Suite 450
Mountain View CALIFORNIA US
Employees: 78
Company Website: https://www.altoneuroscience.com/
Phone: 17732555012
ALTO NEUROSCIENCE INC / ANRO FAQ
What is the stock price of ALTO NEUROSCIENCE INC today?
The current stock price of ANRO is 3.55 USD. The price decreased by -10.13% in the last trading session.
What is the ticker symbol for ALTO NEUROSCIENCE INC stock?
The exchange symbol of ALTO NEUROSCIENCE INC is ANRO and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is ANRO stock listed?
ANRO stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for ALTO NEUROSCIENCE INC stock?
13 analysts have analysed ANRO and the average price target is 12.04 USD. This implies a price increase of 239.04% is expected in the next year compared to the current price of 3.55. Check the ALTO NEUROSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALTO NEUROSCIENCE INC worth?
ALTO NEUROSCIENCE INC (ANRO) has a market capitalization of 95.74M USD. This makes ANRO a Micro Cap stock.
How many employees does ALTO NEUROSCIENCE INC have?
ALTO NEUROSCIENCE INC (ANRO) currently has 78 employees.
What are the support and resistance levels for ALTO NEUROSCIENCE INC (ANRO) stock?
ALTO NEUROSCIENCE INC (ANRO) has a resistance level at 3.9. Check the full technical report for a detailed analysis of ANRO support and resistance levels.
Should I buy ALTO NEUROSCIENCE INC (ANRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANRO, evaluating the profitability, health, valuation and growth aspects
- ALTO NEUROSCIENCE INC (ANRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALTO NEUROSCIENCE INC (ANRO) Sales and EPS estimates to see what analysts future expectations are.
- ALTO NEUROSCIENCE INC (ANRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALTO NEUROSCIENCE INC (ANRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALTO NEUROSCIENCE INC (ANRO) Stock Chart to make your own analysis
- ALTO NEUROSCIENCE INC (ANRO) Latest news and press-releases to stay up to date.
Does ALTO NEUROSCIENCE INC (ANRO) stock pay dividends?
ANRO does not pay a dividend.
When does ALTO NEUROSCIENCE INC (ANRO) report earnings?
ALTO NEUROSCIENCE INC (ANRO) will report earnings on 2025-03-20, after the market close.
What is the Price/Earnings (PE) ratio of ALTO NEUROSCIENCE INC (ANRO)?
ALTO NEUROSCIENCE INC (ANRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.75).
What is the Short Interest ratio of ALTO NEUROSCIENCE INC (ANRO) stock?
The outstanding short interest for ALTO NEUROSCIENCE INC (ANRO) is 15.97% of its float. Check the ownership tab for more information on the ANRO short interest.
ANRO Technical Analysis
ANRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANRO. ANRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ANRO Financial Highlights
Over the last trailing twelve months ANRO reported a non-GAAP Earnings per Share(EPS) of -9.75. The EPS decreased by -31.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.98% | ||
| ROE | -34.81% | ||
| Debt/Equity | 0.05 |
ANRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ANRO. The Buy consensus is the average rating of analysts ratings from 13 analysts.